← Leaderboards
Carrie Kimberly Jones
Vanderbilt University
$9,423,953
Attributed
$9,951,900
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$9,951,900 · 7
By mechanism
R01$6,418,479 · 3
U01$2,090,995 · 1
U19$1,368,863 · 2
F32$73,563 · 1
Top collaborators
- Craig Lindsley3 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- P Jeffrey Conn$37,782,937
- Craig Lindsley$38,671,033
- Dave Weaver$2,295,118
- Thilo Womelsdorf$6,643,968
- Jerri Michelle Rook$4,711,471
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoReceptorNovel StrategiesSeriesBinding SitesCognitionPre-ClinicalImpaired CognitionAgonistGlutamatesResponseMediatingMuscarinic Acetylcholine ReceptorNeurotransmissionAcetylcholineSignal TransductionDoseAnalogRattusBehavioralNovel TherapeuticsRodent ModelAlzheimer&AposReporting
Grant awards (24)
M1 PAMs for Age-Related Cognitive Impairments$736,423
R01 · FY2021 · AG · contact PI
M1 PAMs for Age-Related Cognitive Impairments$666,679
R01 · FY2020 · AG · contact PI
M1 PAMs for Age-Related Cognitive Impairments$679,797
R01 · FY2019 · AG · contact PI
M1 PAMs for Age-Related Cognitive Impairments$695,741
R01 · FY2018 · AG · contact PI
M1 PAMs for Age-Related Cognitive Impairments$663,797
R01 · FY2017 · AG · contact PI
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$353,142
R01 · FY2017 · DA
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$349,610
R01 · FY2016 · DA
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$353,142
R01 · FY2015 · DA
Evaluation of VU0409106 in preclinical models of Major Depressive Disorder$348,885
U19 · FY2015 · MH · contact PI
Development of a Functional Biomarker for M1 PAM target engagement$283,445
U19 · FY2015 · MH · contact PI
Invivo DMPK$421,636
U01 · FY2014 · MH · contact PI
Evaluation of VU0409106 in preclinical models of Major Depressive Disorder$348,885
U19 · FY2014 · MH · contact PI
Invivo DMPK$404,725
U01 · FY2013 · MH · contact PI
Evaluation of VU0409106 in preclinical models of Major Depressive Disorder$387,648
U19 · FY2013 · MH · contact PI
M4 Positive Allosteric Modulators for the Treatment of Schizophrenia$370,656
R01 · FY2013 · MH · contact PI
Invivo DMPK$421,539
U01 · FY2012 · MH · contact PI
M4 Positive Allosteric Modulators for the Treatment of Schizophrenia$386,100
R01 · FY2012 · MH · contact PI
Invivo DMPK$420,135
U01 · FY2011 · MH · contact PI
M4 Positive Allosteric Modulators for the Treatment of Schizophrenia$386,100
R01 · FY2011 · MH · contact PI
Invivo DMPK$422,960
U01 · FY2010 · MH · contact PI
M4 Positive Allosteric Modulators for the Treatment of Schizophrenia$389,792
R01 · FY2010 · MH · contact PI
M4 Positive Allosteric Modulators for the Treatment of Schizophrenia$387,500
R01 · FY2009 · MH · contact PI
mGluR5 allosteric potentiators:In Vivo Characterization$19,571
F32 · FY2008 · MH · contact PI
mGluR5 allosteric potentiators:In Vivo Characterization$53,992
F32 · FY2006 · MH · contact PI